CellCentric
Phase 1We are developing inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP, for the treatment of multiple myeloma and other cancers.
Founded
2004
Focus
Drug Delivery
About
We are developing inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP, for the treatment of multiple myeloma and other cancers.
Funding History
5Total raised: $234M
Venture$120MUndisclosedMay 19, 2025
Series B$29MM VenturesOct 15, 2021
Series B$50MForbionJun 15, 2021
Series A$15MM VenturesJun 15, 2019
Company Info
TypePrivate
Founded2004
LocationCambridge, United Kingdom
StagePhase 1
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile